[go: up one dir, main page]

MA27465A1 - Nouveaux analogues d'adenosine et leur utilisation comme agents pharmaceutiques - Google Patents

Nouveaux analogues d'adenosine et leur utilisation comme agents pharmaceutiques

Info

Publication number
MA27465A1
MA27465A1 MA28022A MA28022A MA27465A1 MA 27465 A1 MA27465 A1 MA 27465A1 MA 28022 A MA28022 A MA 28022A MA 28022 A MA28022 A MA 28022A MA 27465 A1 MA27465 A1 MA 27465A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical agents
adenosine analogs
novel adenosine
compounds
novel
Prior art date
Application number
MA28022A
Other languages
English (en)
Inventor
Siegfried Stengelin
Gerhard Jaehne
Andreas Herling
Guenter Mueller
Franz Jakob Hock
Michael R Myers
Antony Bigot
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of MA27465A1 publication Critical patent/MA27465A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur des composés de formule générale (I) dans laquelle: R1, A, B, Q, T, W et X ont les significations données dans la description. Ces composés s'avèrent utiles pour l'élaboration de médicaments: traitant la résistance à l'insuline, le diabète de type 2, les syndromes du métabolisme, les troubles lipidiques, ou les maladies cardio-vasculaires, ou à action anti- lipolytique.
MA28022A 2002-06-27 2004-12-24 Nouveaux analogues d'adenosine et leur utilisation comme agents pharmaceutiques MA27465A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02014324A EP1375508A1 (fr) 2002-06-27 2002-06-27 Dérivés de l'adénosine N6-substitués et leur utilisation comme médicament

Publications (1)

Publication Number Publication Date
MA27465A1 true MA27465A1 (fr) 2005-08-01

Family

ID=29716849

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28022A MA27465A1 (fr) 2002-06-27 2004-12-24 Nouveaux analogues d'adenosine et leur utilisation comme agents pharmaceutiques

Country Status (19)

Country Link
EP (2) EP1375508A1 (fr)
JP (1) JP2006501178A (fr)
KR (1) KR20050014888A (fr)
CN (1) CN1671728A (fr)
AR (1) AR039697A1 (fr)
AU (1) AU2003280141A1 (fr)
BR (1) BR0312428A (fr)
CA (1) CA2490253A1 (fr)
HR (1) HRP20041209A2 (fr)
IL (1) IL165934A0 (fr)
MA (1) MA27465A1 (fr)
MX (1) MXPA04012815A (fr)
NO (1) NO20050398L (fr)
PE (1) PE20040584A1 (fr)
PL (1) PL375197A1 (fr)
RU (1) RU2005101872A (fr)
TW (1) TW200500376A (fr)
WO (1) WO2004003002A1 (fr)
ZA (1) ZA200410062B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51680B (sr) 2005-09-21 2011-10-31 Pfizer Limited Derivati karboksamida kao antagonisti receptora muskarina
JP2007153789A (ja) * 2005-12-05 2007-06-21 Mitsui Chemicals Inc 光学活性３−アミノピロリジン誘導体の製造方法
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
CN119039201A (zh) * 2024-07-19 2024-11-29 苏州汉德创宏生化科技有限公司 一种(s)-1-叔丁氧羰基-3-氨基吡咯烷的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545645A1 (de) * 1965-12-06 1969-08-21 Boehringer Mannheim Gmbh Verfahren zur Herstellung von disubstituierten Adenosin-Derivaten
AU575438B2 (en) * 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4755594A (en) * 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
AU8276187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
WO1997033591A1 (fr) * 1996-03-13 1997-09-18 Novo Nordisk A/S Procede de traitement d'affections associees aux cytokines chez les mammiferes
UA51716C2 (uk) * 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
EP0983768A1 (fr) * 1997-05-23 2000-03-08 Nippon Shinyaku Co., Ltd. Preparation medicamenteuse aux fins de la prevention et du traitement des hepatopathies
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
KR20050014888A (ko) 2005-02-07
PE20040584A1 (es) 2004-11-03
HRP20041209A2 (en) 2005-08-31
IL165934A0 (en) 2006-01-15
RU2005101872A (ru) 2005-08-10
TW200500376A (en) 2005-01-01
EP1527083A1 (fr) 2005-05-04
EP1375508A1 (fr) 2004-01-02
AR039697A1 (es) 2005-03-09
CA2490253A1 (fr) 2004-01-08
CN1671728A (zh) 2005-09-21
AU2003280141A1 (en) 2004-01-19
BR0312428A (pt) 2005-04-26
NO20050398L (no) 2005-01-25
PL375197A1 (en) 2005-11-28
WO2004003002A1 (fr) 2004-01-08
JP2006501178A (ja) 2006-01-12
ZA200410062B (en) 2008-08-27
MXPA04012815A (es) 2005-02-24

Similar Documents

Publication Publication Date Title
EP1502603A4 (fr) MEDICAMENT CONTENANT UNE COMPOSITION D'ANTICORPS APPROPRIEE AU PATIENT SOUFFRANT DE POLYMORPHISME FC gammma RIIIA
TNSN00202A1 (fr) Derives de n-[(purine - 2- yl) methyl]-sulfonamide nouveaux, procede pour leur preparation et compositions les contenant
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
Aughey et al. Chronic intermittent hypoxia and incremental cycling exercise independently depress muscle in vitro maximal Na+-K+-ATPase activity in well-trained athletes
KR900014367A (ko) 피롤리딘 유도체
TR200003333T2 (tr) Ensülin direngenliği ve hiperglisemi tedavisinde yararlı benzotiyofenler
DK2157192T3 (da) Sammensætninger til diagnose og terapi af sygdomme forbundet med afvigende ekspression af futriner (R-spondiner)
DK0975595T3 (da) Kokainanaloger
BRPI0409109A (pt) novos compostos
BRPI0410746A (pt) compostos e composições imunossupressoras
BR9811260A (pt) Pequenas moléculas úteis no tratamento de doença inflamatória
AR015358A1 (es) Antagonistas de la endotelina: n-[[2'-[[(4,5-dimetil-3-isoxazolil)amino]sulfonil]-4-(2-oxazolil)[1,1'-bifenil]-2-il]metil]-n,3,3-trimetilbutanamida yn-(4,5-demitil-3-isoxazolil)-2'-[(3,3-dimetil-2-oxo-1-pirrolidinil)metil]-4'-(2-oxazolil)[1,1'-bifenil]-2-sulfonamida y sales de los mismos y las compo
BRPI0517947A (pt) composto de piridazina, composições e métodos
MA28111A1 (fr) Derives des
DK1106178T3 (da) Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose
DE60237528D1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
MA30596B1 (fr) 18-methyl-19-nor-androst-4-en-17,17-spiroethers (18-methyl-19-nor-20-spirox-4-en-3-one) et preparations pharmaceutiques les contenant.
MA29227B1 (fr) 4-phenyltetrahydroisoquinoline substituees, leur procedes de fabrication, leur utilisation en tant que medicament et medicament les contenant
MA27741A1 (fr) Derives diarylcycloalkyles , procede pour leur production, et leur utilisation en tant que medicaments
TR200402529T4 (tr) Yeni Fenalliloksi fenil türevleri.
MA27465A1 (fr) Nouveaux analogues d'adenosine et leur utilisation comme agents pharmaceutiques
ATE87484T1 (de) Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
EP1602366A4 (fr) Timbre transdermique pour l'administration de medicaments ioniques
DE502004005560D1 (de) Pharmazeutische formulierungen enthaltend hochreine basen von 3,3-diphenylpropylaminmonoestern
TW200503691A (en) Therapeutic agents